Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin

Nishida, Urara; Kato, Mototsugu; Mutsumi, Nishida; Kamada, Go; Yoshida, Takeshi; Ono, Shouko; Shimizu, Yuichi; Asaka, Masahiro

doi:10.3748/wjg.v17.i2.226

Cited by 7 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, when we assessed the interventions' effect in studies without acid secretion inhibiting drugs as a placebo, we also saw its benefit. 10,34,46 All medications, besides ecabet sodium, 40 included in the meta-analysis also showed a favourable impact on mucosal integrity and injury improvement in the qualitative analysis. Polaprezinc treatment, with its anti-inflammatory effect and intercellular tight-junction protection, could also reduce the number of reddened lesions and the Lewis score.…”

Section: Discussionmentioning

confidence: 90%

“…Our systematic search provided a total of 3341 duplicate-free records. After title, abstract and full-text selection, we identified 26 RCTs 9–12,25–47 for our qualitative synthesis. We included 12 articles on the prevention 9,11,12,26–29,35,38,40,42,46 and 6 articles on the treatment 31,32,39,44,45,47 of NSAID-induced SBE in the quantitative synthesis.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, when we assessed the interventions’ effect in studies without acid secretion inhibiting drugs as a placebo, we also saw its benefit. 10 , 34 , 46 …”

Section: Discussionmentioning

confidence: 99%

“…39 In 11 articles, the bias regarding randomization process domain was at 'some concerns'. 6,11,34,35,[37][38][39][40][41][42]46 Measurement of the outcome, missing outcome data and deviation from the intended intervention domains were at the lowest risk of bias in all the articles.…”

Section: Risk Of Bias Assessmentmentioning

confidence: 96%

See 3 more Smart Citations

Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials

Teutsch

Boros

Váncsa

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Small bowel enteropathy (SBE) is a complication of nonsteroidal anti-inflammatory drug (NSAID) therapy occurring in 71% of NSAID users. We aimed to analyse the efficacy and safety of medications to prevent and treat NSAID-induced SBE in randomized controlled trials (RCTs). Methods: This review was registered on PROSPERO (CRD42021223371). We systematically searched four databases until 20 October for comparing mucoprotective (MP), antibiotic and probiotic treatments to placebo, proton-pump inhibitors (PPIs) or histamine-2 (H2) receptor antagonists in NSAID-associated small intestinal injuries. The main outcomes were mucosal integrity, mucosal breaks after treatment, mucosal injury improvement and complete healing of mucosal breaks. Meta-analytical calculations for weighted mean differences (WMDs) and odds ratios (ORs) were performed with the random-effects model and interpreted with 95% confidence intervals (CIs). Results: A total of 18 RCTs were included in the quantitative synthesis. MP medications administered preventively reduced the number of mucosal erosions (WMD = −1.24, CI: −2.15 to −0.34) and lead to a significantly lower chance of developing mucosal breaks after treatment (OR = 0.38, CI: 0.16–0.93). MP therapy was associated with a higher rate of complete healing of mucosal breaks (OR = 5.39, CI: 2.79–10.42). In the qualitative synthesis, there were tendencies for a lower increase in the mean number of mucosal breaks and reddened lesions with prophylactic and a higher decrease in mucosal breaks with therapeutic MP drug administration. Conclusion: MP treatment administered with NSAIDs can prevent and reduce small intestinal mucosal lesions.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Resultsmentioning

confidence: 99%

“…In addition, when we assessed the interventions’ effect in studies without acid secretion inhibiting drugs as a placebo, we also saw its benefit. 10 , 34 , 46 …”

Section: Discussionmentioning

confidence: 99%

Section: Risk Of Bias Assessmentmentioning

confidence: 96%

See 2 more Smart Citations

Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials

Teutsch

Boros

Váncsa

et al. 2021

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Rebamipide (100mg TID) reduced intestinal lesions induced by diclofenac (25 mg TID) given for 14 days. In addition, Nishida et al [39] recently studied the effect of rebamipide on the intestinal lesions induced by low dose entericcoated aspirin in 10 HVs, and found that aspirin (100 mg) given once a day for 14 days caused lesions (observed by CE) and a decrease of mucosal blood flow (measured by contrast-enhanced ultrasonography) in the small intestine, and these effects were prevented by rebamipide (100 mg TID).…”

Section: Rebamipidementioning

confidence: 99%

Management of NSAID/Aspirin-Induced Small Intestinal Damage by GI-Sparing NSAIDs, Anti-Ulcer Drugs and Food Constituents

Satoh¹,

Takeuchi²

2012

CMC

View full text Add to dashboard Cite

Recent advances in endoscopic techniques such as capsule endoscopy have revealed that aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs) often cause mucosal lesions not only in the upper gastrointestinal tract, but also in the small intestine in humans. Gastric and duodenal lesions caused by NSAIDs can be treated with anti-secretory agents such as proton pump inhibitors or histamine H2-receptor antagonists; however, these drugs are ineffective in treating NSAID-induced lesions in the small intestine. Furthermore, there are few effective agents for the treatment of small intestinal lesions. Therefore, identification of effective therapies for the treatment of NSAID/aspirin-induced small intestinal lesions remains an urgent priority. In the present review, we focus on novel pharmacological treatments to prevent or reduce NSAID-induced intestinal lesions, i.e., 1) GI-sparing NSAIDs (NO- or H2S-NSAIDs, NSAIDs mixed with phosphatidylcholine); 2) anti-ulcer drugs such as mucosal protective agents (misoprostol, rebamipide, teprenone, etc.) and anti-secretory agents (lansoprazole, etc.); 3) antibiotics (metronidazole) and probiotics (Lactobacillus sp.); and 4) food constituents (lactoferrin and soluble dietary fibers). We surveyed data from clinical trials evaluating these novel treatments. Also reviewed herein were the pros and cons of the novel protective methods from the standpoint of safety, efficacy, convenience, and cost.

show abstract

Rebamipide Helps Defend Against Nonsteroidal Anti-Inflammatory Drugs Induced Gastroenteropathy: A Systematic Review and Meta-Analysis

et al. 2013

View full text Add to dashboard Cite

show abstract

Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin

Abstract: Short-term administration of low-dose aspirin is associated with small bowel injuries and blood flow.

Cited by 7 publications

References 14 publications

Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials

Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials

Management of NSAID/Aspirin-Induced Small Intestinal Damage by GI-Sparing NSAIDs, Anti-Ulcer Drugs and Food Constituents

Rebamipide Helps Defend Against Nonsteroidal Anti-Inflammatory Drugs Induced Gastroenteropathy: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About